Olink Holding AB (publ) (OLK)
| Market Cap | 4.47B |
| Revenue (ttm) | 54.07M |
| Net Income (ttm) | -6.78M |
| Shares Out | 119.01M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 9 |
| Last Price | $37.60 |
| Previous Close | $37.75 |
| Change ($) | -0.15 |
| Change (%) | -0.40% |
| Day's Open | 37.50 |
| Day's Range | 37.20 - 38.35 |
| Day's Volume | 109,702 |
| 52-Week Range | 28.97 - 42.20 |
Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of its...
Olink Holding, which provides a platform of proteome analysis products for biomedical research, filed on Wednesday with the SEC to raise up to $100 million in a US initial public offering.
Olink Holding AB (publ) has filed to go public with an IPO on the NASDAQ.
About OLK
Our purpose is to enable and accelerate the field of proteomics by providing a platform of products and services that are deployed across major biopharmaceutical companies and leading clinical and academic institutions, to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. We support 30 of the world’s largest 40 biopharmaceutical companies by 2019 revenue, including all of the largest 19, and many leading academic institutions. Our current offering is based on our pr... [Read more...]
| Industry Diagnostics & Research | IPO Date Mar 25, 2021 |
| CEO Jon Heimer | Employees 214 |
| Stock Exchange NASDAQ | Ticker Symbol OLK |
Financial Performance
In 2020, Olink Holding's revenue was $54.07 million, an increase of 29.68% compared to the previous year's $41.69 million. Losses were -$6.78 million, -62.08% less than in 2019.